EUVIMEDEUVIMED entdecken
Crossref

Continuous venetoclax in treatment‐naive TP 53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study

Andrea Visentin iD, Francesca Romana Mauro iD, Lydia Scarfò, Massimo Gentile, Lucia Farina, Gianluigi Reda iD, Isacco Ferrarini iD, Giulia Proietti, Enrico Derenzini, Francesca Cibien, Candida Vitale, Alessandro Sanna iD und 18 weitere

American Journal of Hematology · 2023

DOI: 10.1002/ajh.27009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2023. Verfasst von Andrea Visentin und 29 weiteren Autor:innen. Beteiligte Einrichtung: Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padua, Italy. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 13 Literaturangaben. Gefördert von: Associazione Italiana per la Ricerca sul Cancro.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellAntineoplastic AgentsHumansBridged Bicyclo Compounds, HeterocyclicSulfonamidesAntineoplastic Combined Chemotherapy ProtocolsTumor Suppressor Protein p53

Substanzen

venetoclaxAntineoplastic AgentsBridged Bicyclo Compounds, HeterocyclicSulfonamidesTP53 protein, humanTumor Suppressor Protein p53

Autor:innen und Institutionen

  • Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padua, Italy.
  • Veneto Institute of Molecular Medicine, Padua, Italy.
  • Hematology, Department of Translational and Precision Medicine, "Sapienza" University, Rome, Italy.
  • Strategic Research Program on CLL, Università Vita-salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy.
  • Hematology Unit, Azienda Ospedaliera of Cosenza, Cosenza, Italy.
  • Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy.

ORCID-Profile: Andrea Visentin, Francesca Romana Mauro, Gianluigi Reda, Isacco Ferrarini, Alessandro Sanna, Gian Matteo Rigolin, Paolo Sportoletti, Luca Laurenti, Stefano Molica

Förderung

  • Associazione Italiana per la Ricerca sul Cancro

Zitieren

APA

Visentin, A., Mauro, F. R., Scarfò, L., Gentile, M., Farina, L., Reda, G., Ferrarini, I., Proietti, G., Derenzini, E., Cibien, F., Vitale, C., Sanna, A., Pietrasanta, D., Marchetti, M., Murru, R., Rigolin, G. M., Sportoletti, P., Trimarco, V., Cavarretta, C. A., …, & Trentin, L. (2023). Continuous venetoclax in treatment‐naive TP 53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study. American Journal of Hematology. https://doi.org/10.1002/ajh.27009

Vancouver

Visentin A, Mauro FR, Scarfò L, Gentile M, Farina L, Reda G, et al. Continuous venetoclax in treatment‐naive TP 53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study. American Journal of Hematology. 2023. doi:10.1002/ajh.27009

BibTeX
@article{Visentin2023,
  author = {Visentin, Andrea and Mauro, Francesca Romana and Scarfò, Lydia and Gentile, Massimo and Farina, Lucia and Reda, Gianluigi and Ferrarini, Isacco and Proietti, Giulia and Derenzini, Enrico and Cibien, Francesca and Vitale, Candida and Sanna, Alessandro and Pietrasanta, Daniela and Marchetti, Monia and Murru, Roberta and Rigolin, Gian Matteo and Sportoletti, Paolo and Trimarco, Valentina and Cavarretta, Chiara Adele and Angotzi, Francesco and Cellini, Alessandro and Ruocco, Valeria and Zatta, Ivan and Laurenti, Luca and Molica, Stefano and Coscia, Marta and Ghia, Paolo and Foà, Robin and Cuneo, Antonio and Trentin, Livio},
  title = {Continuous venetoclax in treatment‐naive TP 53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study},
  journal = {American Journal of Hematology},
  year = {2023},
  doi = {10.1002/ajh.27009}
}
Kostenlos starten →